United States Biotechnology & Medical Research

Spyre Therapeutics Inc (SYRE)

Track

Spyre Therapeutics experienced significant insider trading activity recently, with executives and directors executing thirty-five sales totaling over 825 million dollars. These divestments followed a strong performance in the latest earnings report. Despite the stock price rising 37.3% over ninety days, leadership consistently offloaded shares, reflecting a net negative sentiment among key corporate stakeholders.
Ticker: SYRE Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Spyre Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 7 Aug 2026
Value US$1,922,202.24 | Price 160.62 | Shares 58,100 (-17.1%)
Planned sale 7 Aug 2026
Value US$2,712,825.25 | Price 432.69 | Shares 61,287 (+39.9%)
Planned sale 7 Aug 2026
Value US$100,000.00 | Price 104.47 | Shares 1,000 (-100.0%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-10 2026-08-07 PlS Planned sale
2.3
Albers Jeffrey W.
Non-Executive Director
58,100 -17.1%
160.62
US$1,922,202 		58,100 -17.1% 160.62 US$1,922,202
2026-08-10 2026-08-07 PlS Planned sale
2.3
Albers Jeffrey W.
Non-Executive Director
61,287 +39.9%
432.69
US$2,712,825 		61,287 +39.9% 432.69 US$2,712,825
2026-08-10 2026-08-07 PlS Planned sale
2.3
Albers Jeffrey W.
Non-Executive Director
53,807 +20.2%
436.03
US$3,055,570 		53,807 +20.2% 436.03 US$3,055,570
2026-08-07 2026-08-07 PrS Proposed sale
2.3
SESSIONS, LLC

Director

Non-Executive Director
1,000
103.42
US$100,000 		1,000 103.42 US$100,000
2026-08-07 2026-08-07 PrS Proposed sale
2.3
JEFFREY ALBERS

Director

Non-Executive Director
1,000
103.42
US$100,000 		1,000 103.42 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
1,000 -0.1%
97.10
US$100,000 		1,000 -0.1% 97.10 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
1,000 -2.3%
96.30
US$100,000 		1,000 -2.3% 96.30 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
1,000 -4.8%
95.21
US$100,000 		1,000 -4.8% 95.21 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,000 -0.0%
97.46
US$100,000 		1,000 -0.0% 97.46 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,000 -0.2%
96.82
US$100,000 		1,000 -0.2% 96.82 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,000 -1.0%
95.93
US$100,000 		1,000 -1.0% 95.93 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,000 -1.2%
95.10
US$100,000 		1,000 -1.2% 95.10 US$100,000
2026-08-05 2026-08-03 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,000 -0.1%
93.97
US$100,000 		1,000 -0.1% 93.97 US$100,000
2026-08-03 2026-08-03 PrS Proposed sale
1.8
SCOTT BURROWS

Officer

Officer
1,000
98.33
US$100,000 		1,000 98.33 US$100,000
2026-07-02 2026-07-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
1,725 -1.7%
88.37
US$152,438 		1,725 -1.7% 88.37 US$152,438
2026-07-02 2026-07-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
5,775 -5.5%
87.55
US$505,601 		5,775 -5.5% 87.55 US$505,601
2026-07-02 2026-07-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
1,834 -100.0%
88.34
US$162,016 		1,834 -100.0% 88.34 US$162,016
2026-07-02 2026-07-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
6,500 -78.0%
87.52
US$568,880 		6,500 -78.0% 87.52 US$568,880
2026-07-02 2026-07-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
590 -0.1%
88.91
US$52,457 		590 -0.1% 88.91 US$52,457
2026-07-02 2026-07-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
4,234 -0.7%
88.12
US$373,100 		4,234 -0.7% 88.12 US$373,100
2026-07-02 2026-07-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
10,176 -1.7%
87.44
US$889,789 		10,176 -1.7% 87.44 US$889,789
2026-07-01 2026-07-01 PrS Proposed sale
1.5
CAMERON TURTLE

Director; Officer

Executive Director
45,000
88.78
US$3,995,100 		45,000 88.78 US$3,995,100
2026-06-26 2026-06-25 S Sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
10,000 -9.3%
87.14
US$871,400 		10,000 -9.3% 87.14 US$871,400
2026-06-26 2026-06-25 S Sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
5,000 -4.4%
87.12
US$435,600 		5,000 -4.4% 87.12 US$435,600
2026-06-25 2026-06-25 PrS Proposed sale
1.8
SCOTT BURROWS

Officer

Officer
15,000
87.13
US$1,306,980 		15,000 87.13 US$1,306,980
2026-06-23 2026-06-23 PrS Proposed sale
3.3
Fairmount Healthcare Fund II L.P.

Director

Non-Executive Director
4,684,781
85.31
US$399,658,667 		4,684,781 85.31 US$399,658,667
2026-06-23 2026-06-23 S Sale
3.3
Fairmount Funds Management LLC
Non-Executive Director
4,684,781 -100.0%
85.31
US$399,658,667 		4,684,781 -100.0% 85.31 US$399,658,667
2026-06-23 2026-06-22 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
20,000 -22.6%
100.00
US$2,000,000 		20,000 -22.6% 100.00 US$2,000,000
2026-06-22 2026-06-22 PrS Proposed sale
MICHAEL HENDERSON

Director

Non-Executive Director
20,000
88.34
US$1,766,800 		20,000 88.34 US$1,766,800
2026-06-22 2026-06-22 PrS Proposed sale
MICHAEL HENDERSON

Director

Non-Executive Director
20,000
88.34
US$1,766,800 		20,000 88.34 US$1,766,800
2026-06-03 2026-06-03 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
8,333 -100.0%
75.00
US$624,975 		8,333 -100.0% 75.00 US$624,975
2026-06-03 2026-06-03 PrS Proposed sale
SHELDON SLOAN

Officer

Officer
16,667
69.16
US$1,152,690 		16,667 69.16 US$1,152,690
2026-06-03 2026-06-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,294 -0.5%
71.38
US$235,126 		3,294 -0.5% 71.38 US$235,126
2026-06-03 2026-06-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
8,149 -1.3%
70.50
US$574,504 		8,149 -1.3% 70.50 US$574,504
2026-06-03 2026-06-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,557 -0.6%
69.40
US$246,856 		3,557 -0.6% 69.40 US$246,856
2026-06-03 2026-06-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
3,100 -3.1%
72.06
US$223,386 		3,100 -3.1% 72.06 US$223,386
2026-06-03 2026-06-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
2,599 -2.5%
70.77
US$183,931 		2,599 -2.5% 70.77 US$183,931
2026-06-03 2026-06-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
1,801 -1.7%
69.75
US$125,620 		1,801 -1.7% 69.75 US$125,620
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
19,269 -17.9%
75.35
US$1,451,919 		19,269 -17.9% 75.35 US$1,451,919
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
24,814 -18.7%
74.76
US$1,855,095 		24,814 -18.7% 74.76 US$1,855,095
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
33,513 -20.2%
73.72
US$2,470,578 		33,513 -20.2% 73.72 US$2,470,578
2026-05-08 2026-05-08 PlS Planned sale
HENDERSON MICHAEL THOMAS
Non-Executive Director
2,404 -1.4%
72.57
US$174,458 		2,404 -1.4% 72.57 US$174,458
2026-05-08 2026-05-08 PrS Proposed sale
MICHAEL HENDERSON

Director

Non-Executive Director
80,000
73.10
US$5,848,000 		80,000 73.10 US$5,848,000
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
400 -100.0%
75.37
US$30,148 		400 -100.0% 75.37 US$30,148
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
5,059 -92.7%
74.60
US$377,401 		5,059 -92.7% 74.60 US$377,401
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
10,358 -65.5%
73.74
US$763,799 		10,358 -65.5% 73.74 US$763,799
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
12,777 -44.7%
72.94
US$931,954 		12,777 -44.7% 72.94 US$931,954
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
8,777 -23.5%
71.56
US$628,082 		8,777 -23.5% 71.56 US$628,082
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
19,656 -34.5%
70.61
US$1,387,910 		19,656 -34.5% 70.61 US$1,387,910
2026-05-01 2026-05-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
21,306 -27.2%
69.53
US$1,481,406 		21,306 -27.2% 69.53 US$1,481,406
2026-05-01 2026-05-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
12,500 -11.3%
71.37
US$892,125 		12,500 -11.3% 71.37 US$892,125
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
300 -0.0%
74.96
US$22,488 		300 -0.0% 74.96 US$22,488
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,700 -0.3%
74.23
US$126,191 		1,700 -0.3% 74.23 US$126,191
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,100 -0.5%
73.14
US$226,734 		3,100 -0.5% 73.14 US$226,734
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
1,000 -0.2%
71.76
US$71,760 		1,000 -0.2% 71.76 US$71,760
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
3,600 -0.6%
70.77
US$254,772 		3,600 -0.6% 70.77 US$254,772
2026-05-01 2026-05-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
5,300 -0.8%
69.54
US$368,562 		5,300 -0.8% 69.54 US$368,562
2026-05-01 2026-05-01 PrS Proposed sale
1.8
SCOTT BURROWS

Officer

Officer
27,500
74.45
US$2,047,375 		27,500 74.45 US$2,047,375
2026-05-01 2026-05-01 PrS Proposed sale
SHELDON SLOAN

Officer

Officer
78,333
74.45
US$5,831,892 		78,333 74.45 US$5,831,892
2026-04-03 2026-04-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
2,656 -0.4%
49.92
US$132,588 		2,656 -0.4% 49.92 US$132,588
2026-04-03 2026-04-01 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
12,344 -1.9%
49.20
US$607,325 		12,344 -1.9% 49.20 US$607,325
2026-04-03 2026-04-01 PlS Planned sale
Sloan Sheldon

Chief Medical Officer

Officer
7,958 -100.0%
50.00
US$397,900 		7,958 -100.0% 50.00 US$397,900
2026-04-03 2026-04-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
1,300 -1.3%
49.98
US$64,974 		1,300 -1.3% 49.98 US$64,974
2026-04-03 2026-04-01 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
6,200 -5.9%
49.21
US$305,102 		6,200 -5.9% 49.21 US$305,102
2026-04-01 2026-04-01 PrS Proposed sale
SHELDON SLOAN

Officer

Officer
7,958
50.44
US$401,402 		7,958 50.44 US$401,402
2026-03-03 2026-03-03 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
200 -0.2%
41.66
US$8,332 		200 -0.2% 41.66 US$8,332
2026-03-03 2026-03-03 PlS Planned sale
1.8
Burrows Scott L

Chief Financial Officer

Officer
2,300 -2.3%
40.56
US$93,288 		2,300 -2.3% 40.56 US$93,288
2026-03-03 2026-03-03 PrS Proposed sale
1.8
SCOTT BURROWS

Officer

Officer
10,000
42.49
US$424,900 		10,000 42.49 US$424,900
2026-03-03 2026-03-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
9,100 -1.4%
42.49
US$386,659 		9,100 -1.4% 42.49 US$386,659
2026-03-03 2026-03-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
5,900 -0.9%
41.73
US$246,207 		5,900 -0.9% 41.73 US$246,207
2026-03-02 2026-03-02 PrS Proposed sale
1.5
CAMERON TURTLE

Director; Officer

Executive Director
60,000
43.01
US$2,580,600 		60,000 43.01 US$2,580,600
2026-02-04 2026-02-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
14,043 -2.1%
32.87
US$461,593 		14,043 -2.1% 32.87 US$461,593
2026-02-04 2026-02-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
14,043 -2.1%
32.87
US$461,593 		14,043 -2.1% 32.87 US$461,593
2026-02-04 2026-02-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
957 -0.1%
31.82
US$30,452 		957 -0.1% 31.82 US$30,452
2026-01-06 2026-01-02 PlS Planned sale
1.5
Turtle Cameron

Chief Executive Officer

Executive Director
100 -0.0%
32.39
US$3,239 		100 -0.0% 32.39 US$3,239
Explore more

More insider trading research around Spyre Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America